Is there a role for subcutaneous @entity1483 in the community and hospice management of end-stage XXXX ?

@entity1 @entity712 @entity1483 @entity353
@entity1 with advanced @entity712 ( @entity712 ) can experience 'revolving door' admissions, often for parenteral diuretics, when time at home is precious. Home intravenous diuretic services are patchy. This retrospective review describes 43 consecutive episodes of continuous subcutaneous infusion of @entity1483 (CSCI-F) in 32 advanced @entity712 @entity1 ; 28 episodes aiming to correct fluid balance and prevent hospital admission and 15 aiming to prevent symptoms in the dying. Overall, 26/28 (93%) avoided hospital admission. Weight loss occurred in 20/28 (70%): a median loss of 5.6   kg [interquartile range (IQR) 0.1-8.9]). The daily dose of @entity1483 ranged from 40 to 250   mg. The median number of days on CSCI-F was 10.5 (range 2-48; IQR 6-13.8). Site reactions occurred in 10/43 (23%); all of which were mild except two, one of which required oral antibiotics. Symptoms were controlled in all 15 dying @entity1 . CSCI-F for @entity1 with advanced @entity712 is effective in terms of @entity353 and prevention of hospital admission with the @entity712 nurse specialist playing a key overall management role in selection and monitoring. As the majority of community and hospice nurses have access to and are familiar with CSCI pumps, this practice should be nationally transferable. The role in the dying @entity1 requires further assessment.
